It has become one of the defining stories in Healthcare Technology — and it is reshaping how the sector operates in Sweden. Sweekly spoke with executives, engineers and investors to understand what is really driving the shift, and what it means for the businesses that will live with the consequences.
Reimbursement, not technology, is the gate most digital-health products fail to clear.
The economics
Clinicians are cautious adopters, and rightly so — trust is earned slowly here.
The regulatory path under the new EU framework is longer, and companies have adjusted their timelines accordingly.
“Technology was the easy 20 percent. Reimbursement is the other 80.”— Co-founder
The regulatory path
Point-of-care diagnostics compress days of waiting into minutes.
The data infrastructure behind precision medicine is as important as any single device.
What to watch
- Evidence from independent, multi-site clinical trials
- Reimbursement pathways that make adoption viable
- Interoperability with existing hospital systems
- A clear regulatory path under the new EU rules
The technology
Keeping patients monitored at home is where the clearest cost savings appear.
Evidence from multi-site trials is finally catching up to the marketing claims.
The clinical case
In the clinic, the system reads scans alongside radiologists, flagging what the eye might miss.
Reimbursement, not technology, is the gate most digital-health products fail to clear.
The bottom line
The regulatory path under the new EU framework is longer, and companies have adjusted their timelines accordingly.
Sources & further reading
Written by
Nora SundqvistHealthcare Tech Correspondent
Nora reports on the devices and platforms changing how care is delivered.
Discussion(3)
We're seeing exactly this on the ground. The economics only work once the software ties it together.
Great reporting as always from the Sweekly desk. The data on adoption is eye-opening.
Would love to see a follow-up on how the smaller players are adapting to this shift.